Methods of inhibiting tumor growth using ttk antagonists

Abstract

The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of TTK in a tumor sample from a subject.

1 - 15 . (canceled) 
     
     
         16 . A method of treating a TTK positive basal-like breast cancer tumor in a mammalian subject comprising administering to the subject a therapeutically effective amount of a TTK antagonist. 
     
     
         17 . The method of  claim 16 , wherein the TTK antagonist is selected from the group consisting of an antibody, an antigen-binding fragment of an antibody, a small interfering ribonucleic acid (siRNA), a peptide, a peptidomimetic, an antisense oligonucleotide, and a small molecule. 
     
     
         18 . The method of  claim 16 , wherein said tumor is a metastatic tumor. 
     
     
         19 . The method of  claim 16 , wherein said tumor is a carcinoma. 
     
     
         20 . The method of  claim 16 , further comprising administering one or more other therapeutic agents. 
     
     
         21 - 34 . (canceled)